DSIP Half-Life: How Long It Stays in Your System
How long DSIP stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- 4.0 +/- 0.7 min
- intravenous, dog · Neuroendocrinology 1984, PMID 6379493
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Unclear
- Not named on the 2026 list
- Detection window
- Not found
- None reported as of 2 Oct 2026
DSIP half-life
A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| intravenous | 4.0 +/- 0.7 min | Animal · dog | Neuroendocrinology 1984, PMID 6379493 |
| intravenous | 2.9 min (monkey), 2.0 +/- 0.54 min (rat) | Animal · monkey and rat | Neuroendocrinology 1984, PMID 6379493 |
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of DSIP:
- afternoon before nights 3, 4 and 5, intravenous (Human RCT; Neuropsychobiology 1992, PMID 1299794)
- single morning dose, slow intravenous infusion (Human controlled trial; International journal of clinical pharmacology, therapy, and toxicology 1981, PMID 6895513)
- single dose, intravenous (Human uncontrolled trial; Experientia 1981, PMID 7028502)
- single dose, intravenous (Animal · dog, monkey and rat; Neuroendocrinology 1984, PMID 6379493)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
WADA status unclearDSIP: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Anti-doping labs use tests built for specific substances. Whether a given test detects DSIP, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).
DSIP clearance measured in anesthetized dogs
In anesthetized dogs given DSIP in the vein, the mean half-life was 4.0 minutes.[4]
A monkey and 3 rats given the same measurement showed shorter half-lives of 2.9 and 2.0 minutes.[4]
The assay method used for those half-lives was an enzyme immunoassay with a sensitivity of about 30 pg/ml.[4]
No human half-life in the cache
A PubMed search on 2 Oct 2026 for DSIP terms with half-life or pharmacokinetic words returned 3 records out of 444; the only half-life figures cached here are from dogs, a monkey and rats, and none is from a person.
Calculated from date 2026-10-02; count 3; total peptide records 444; species dog, monkey, rat; source web/src/data/evidence/dsip.json searches. Formula: share = 3 / 444
Common questions
How long does DSIP stay in your system?
Its reported half-life is 4.0 +/- 0.7 min (intravenous, dog); 2.9 min (monkey), 2.0 +/- 0.54 min (rat) (intravenous, monkey and rat). Most of a dose is gone after about four to five half-lives.
What is the half-life of DSIP?
In animals it was measured in minutes, not hours.[4]
Is DSIP on the WADA prohibited list?
It is unclear. DSIP: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
More on DSIP
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.Neuroendocrinology · 1984PMID 6379493Accessed 2 Oct 2026
- 5Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology · 1992PMID 1299794Accessed 2 Oct 2026
- 6Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.International journal of clinical pharmacology, therapy, and toxicology · 1981PMID 6895513Accessed 2 Oct 2026
- 7The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.Experientia · 1981PMID 7028502Accessed 2 Oct 2026
Found an error? Report a correction.